SYN608 / SynRx Therap - LARVOL DELTA

First-in-human study of oral PARG inhibitor SYN608 in advanced solid tumors (AACR 2026) - "Abstract is embargoed at this time."

First-in-human • Metastases • P1 data • Oncology • Solid Tumor

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=105 | Not yet recruiting | Sponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd

New P1 trial • Platinum resistant • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA